<DOC>
	<DOCNO>NCT02223637</DOCNO>
	<brief_summary>The Novartis Meningococcal quadrivalent CRM-197 conjugate vaccine pregnancy registry stablished meet post marketing commitment agree upon CBER prospectively collect data pregnancy exposure Novartis Meningococcal quadrivalent CRM-197 conjugate vaccine . It observational study woman inadvertently immunize Novartis Meningococcal quadrivalent CRM-197 conjugate vaccine within 28 day prior conception time pregnancy part routine care . The objective pregnancy registry evaluate pregnancy outcome among woman immunize Meningococcal quadrivalent CRM-197 conjugate vaccine within 28 day prior conception time pregnancy . The primary outcome interest include major congenital malformation , preterm birth , low birth weight . Other pregnancy outcome collect , include spontaneous abortion stillbirth .</brief_summary>
	<brief_title>Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Sufficient evidence confirm Menveo exposure occur within 28 day prior conception time pregnancy Sufficient information determine whether pregnancy prospectively retrospectively register ( ie , whether outcome pregnancy know time first contact registry ) Date pregnancy exposure register Full reporter ( ie , HCP ) contact information allow followup ( name , address , etc . )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>